Oral capsules

Abstract

This invention relates to an oral capsule comprising: a first shell; a second shell, wherein one end of the first shell is detachably connected to one end of the second shell, such that the interior of the first shell and the interior of the second shell define an accommodating space; and a hair follicle activating powder contained in the accommodating space. The hair follicle activating powder contains proteins, plant extracts, vitamins, and minerals, but does not contain potent drug components. Therefore, it does not cause cardiovascular stress or affect endocrine function, making it suitable for a wider range of people. It can also promote hair follicle nutrition and angiogenesis, maintain hair follicle health, promote hair follicle regeneration, prolong the hair follicle growth phase, promote hair growth, and strengthen hair roots.

Description

Oral capsules Technical Field

[0001] This work relates to a capsule structure, specifically an oral capsule. Prior Technology

[0002] The main causes of hair loss include genetics, stress, nutritional deficiencies, thyroid abnormalities, scalp diseases, medication side effects, and hormonal changes. Hair loss significantly impacts a person's appearance. To inhibit hair loss, products on the market often contain medications such as finasteride and minoxidil. Understandably, to ensure immediate results, these drugs use high concentrations of compounds to forcibly regulate the physiological processes of hair follicle cells, lowering androgen levels or stimulating hair follicles into the growth phase. However, using these drugs directly interferes with vascular or endocrine function, thus carrying risks such as loss of sexual function, palpitations, edema, or decreased blood pressure, and is not suitable for everyone. In view of the above problems, a product with lower irritation, virtually no side effects, and the ability to activate hair follicle cells to improve hair loss and promote hair growth is urgently needed. Summary of the Invention

[0003] The problem this invention aims to solve is to provide a product that is less irritating, has almost no side effects, and can activate hair follicle cells to improve hair loss and promote hair growth.

[0004] To achieve the above objectives, this invention provides an oral capsule comprising: a first shell; a second shell, wherein one end of the first shell is detachably connected to one end of the second shell, such that the interior of the first shell and the interior of the second shell define an accommodating space; and a hair follicle activating powder, which is contained in the accommodating space.

[0005] Even better, wherein the hair follicle activating powder comprises: hydrolyzed egg yolk powder, pea extract, and bird's nest extract.

[0006] Even better, the hair follicle activating powder contains: compound vitamin C, comprehensive B vitamins, compound ferrous glycine, and zinc glycate.

[0007] Even better, the hair follicle activating powder contains: hydrolyzed egg yolk powder, pea extract, bird's nest extract, compound vitamin C, comprehensive B vitamins, compound ferrous glycinate, and zinc glycine.

[0008] More preferably, the hair follicle activating powder, when applied to human follicle dermal papilla cells (HFDPC), can promote the gene expression of vascular endothelial growth factor A (VEGFA), fibroblast growth factor receptor 2 (FGFR2), and insulin-like growth factor 1 (IGF1) in human follicle dermal papilla cells (HFDPC).

[0009] More preferably, the components of the first shell and the second shell include: pure water, colorant, thickener, anti-brittleness agent, gelatin, hydroxypropyl methylcellulose (HPMC), gellan gum, or pullulan.

[0010] More preferably, the first housing or the second housing is transparent, translucent, or opaque.

[0011] More preferably, the first housing comprises: a first hollow tube; a first closed end formed at one end of the first hollow tube; a first open end formed at the other end of the first hollow tube; and a first accommodating subspace formed inside the first housing and connected to the first open end; and the second housing comprises: a second hollow tube; a second closed end formed at one end of the second hollow tube; a second open end formed at the other end of the second hollow tube; and a second accommodating subspace formed inside the second housing and connected to the second open end, wherein: the first open end of the first housing extends from the second open end of the second housing into the second accommodating subspace and engages with the inner edge of the second housing to define the accommodating space.

[0012] More preferably, wherein: the first hollow tube and the second hollow tube are circular tubes, and the outer diameter of the first hollow tube is less than or equal to the inner diameter of the second hollow tube.

[0013] Even better, wherein the first closed end and the second closed end are hemispherical shells.

[0014] The advantage of this invention over previous technologies is that it encapsulates hair follicle activating powder within the space defined by the first and second shells. Since the hair follicle activating powder contains proteins, plant extracts, vitamins, and minerals, but does not contain potent drug ingredients, it is less irritating and has almost no side effects. It will not cause cardiovascular stress or affect endocrine function, and is suitable for a wider range of people. In addition, after oral administration and absorption by the human body, the hair follicle activating powder can increase the gene expression levels of vascular endothelial growth factor A (VEGFA), fibroblast growth factor receptor 2 (FGFR2), and insulin-like growth factor 1 (IGF1) in human hair follicle dermal papillary cells (HFDPC). Therefore, it can promote hair follicle nutrient supply and angiogenesis, maintain hair follicle health, promote hair follicle regeneration, prolong the hair follicle growth phase, promote hair growth, and strengthen hair roots. It has the potential to be used as a hair care product, health care product, or nutritional supplement. Simple Explanation of the Diagram

[0015] Figure 1 is a planar structural diagram used to illustrate the structural characteristics of oral capsules. Implementation

[0016] To make the above and / or other purposes, effects, and features of this invention clearer and easier to understand, preferred embodiments are described in detail below:

[0017] The purpose of this invention is to provide an oral capsule (1), as shown in Figure 1, comprising: a first shell (2); a second shell (3), wherein one end of the first shell (2) is detachably connected to one end of the second shell (3), such that the interior of the first shell (2) and the interior of the second shell (3) define a receiving space (4); and a hair follicle activating powder (5), which is contained in the receiving space (4). In a preferred embodiment, in order to enable the hair follicle activating powder (5) to be released from the oral capsule (1) and absorbed by the human body after oral administration, wherein the components of the first shell (2) and the second shell (3) include: pure water, colorant, thickener, anti-brittleness agent, gelatin, hydroxypropyl methylcellulose (HPMC), gellan gum, or pullulan, but are not limited thereto. In another preferred embodiment, in order to identify whether the hair follicle activating powder (5) is damp or deteriorated, or to prevent light from irradiating the hair follicle activating powder (5), wherein: the first shell (2) or the second shell (3) is transparent, translucent, or opaque.

[0018] More preferably, in order to increase the gene expression of factors related to hair follicle maintenance and hair growth in human dermal papillary cells (HFDPC) after the human body absorbs the hair follicle activating powder (5), the hair follicle activating powder (5) comprises: hydrolyzed egg yolk powder, pea extract, and bird's nest extract, but is not limited thereto. In a preferred embodiment, the hair follicle activating powder (5) comprises: compound vitamin C, comprehensive B vitamins, compound ferrous glycinate, and zinc glycinate, but is not limited thereto. In another preferred embodiment, the hair follicle activating powder (5) comprises: hydrolyzed egg yolk powder, pea extract, bird's nest extract, compound vitamin C, comprehensive B vitamins, compound ferrous glycinate, and zinc glycinate, but is not limited thereto. In another preferred embodiment, the hair follicle activating powder (5) can promote the gene expression of vascular endothelial growth factor A (VEGFA), fibroblast growth factor receptor 2 (FGFR2), and insulin-like growth factor 1 (IGF1) in human follicle dermal papilla cells (HFDPC) after being applied to them.

[0019] More preferably, for encapsulating and storing the hair follicle activating powder (5), the first housing (2) comprises: a first hollow tube (6); a first closed end (7) formed at one end of the first hollow tube (6); a first open end (8) formed at the other end of the first hollow tube (6); and a first accommodating subspace (9) formed inside the first housing (2) and connected to the first open end (8); and the second housing (3) comprises: a second hollow tube (10); and a second closed end (11). A first open end (8) of the first housing (2) is formed at one end of the second hollow tube (10); a second open end (12) is formed at the other end of the second hollow tube (10); and a second accommodating subspace (13) is formed inside the second housing (3) and communicates with the second open end (12), wherein: the first open end (8) of the first housing (2) passes through the second open end (12) of the second housing (3) into the second accommodating subspace (13) and engages with the inner edge of the second housing (3) to define the accommodating space (4). In a preferred embodiment, for ease of oral administration, wherein: the first hollow tube (6) and the second hollow tube (10) are circular tubes, and the outer diameter of the first hollow tube (6) is less than or equal to the inner diameter of the second hollow tube (10). In another preferred embodiment, for ease of oral administration, the first closed end (7) and the second closed end (11) are hemispherical shells, but are not limited thereto.

[0020] The following explains the function and uses of human follicle dermal papilla cells (HFDPC): Specifically, human follicle dermal papilla cells (HFDPC) Human dermal papilla cells (HFDPCs) are key stromal cells in hair follicles, responsible for the formation of hair follicles, controlling hair cycle transitions, and regulating hair growth. Therefore, they are considered the command center or signaling core of hair follicles. The main functions of human dermal papilla cells (HFDPCs) include: (1) Inducing and regulating hair growth: Human dermal papilla cells (HFDPCs) induce hair follicle formation in the early stages of embryonic development and continue to secrete various growth factors and cytokines in adulthood to regulate the growth cycle of hair follicles, including the anagen (growth) phase, catagen (regression) phase, and telogen (resting) phase; (2) Providing nutritional and metabolic support: The area surrounding human dermal papilla cells (HFDPCs) is rich in microvessels, which can transport oxygen and nutrients from the blood to hair matrix cells to support continuous hair growth; (3) Maintaining hair follicle characteristics: Human dermal papilla cells (HFDPCs) can promote hair follicle regeneration and maintain the anagen phase.

[0021] The following explains the mechanism by which this invention can inhibit hair loss and promote hair growth: Specifically, human follicular dermal papillary cells (HFDPCs) contain the following genes: (1) Vascular endothelial growth factor A (VEGFA), which is a major angiogenesis factor. In human follicular dermal papillary cells (HFDPCs), it can promote microvascular formation, increase oxygen and promote nutrient delivery, and is therefore a key regulator of hair follicle growth and activation; (2) Fibroblast growth factor receptor 2 (FGF2), FGFR2 is a transmembrane tyrosine kinase receptor. Human follicular dermal papillary cells (HFDPCs) express a large amount of fibroblast growth factor receptor 2 (FGFR2) on their surface, making them highly sensitive to FGF-type growth factors. They can receive external growth signals to promote cell proliferation and maintain induction capacity. In addition, the activation of fibroblast growth factor receptor 2 (FGFR2) can initiate extracellular signal-regulated kinase 1 / 2 (ERK1 / 2) and phosphatidylinositol 3-kinase / Akt (PI3K / Akt) signaling pathways, thereby delaying cell aging and maintaining hair follicle health; and (3) insulin-like growth factor 1 (IGF1) is a secreted peptide growth factor that can promote hair matrix cell division and prolong the hair growth phase (anagen) while reducing cell apoptosis. Among them, minoxidil, caffeine, and red ginseng extract are included. Components such as extracts can increase the gene expression of insulin-like growth factor 1 (IGF1) and enhance cell activity through the PI3K / Akt and MAPK signaling pathways.

[0022] Furthermore, vascular endothelial growth factor A (VEGFA), fibroblast growth factor receptor 2 (FGFR2), and insulin-like growth factor 1 (IGF1) have synergistic effects in the hair follicle microenvironment. VEGFA promotes angiogenesis, FGFR2 maintains the activity of human follicular dermal papilla cells (HFDPC), and IGF1 promotes hair matrix cell proliferation. These three factors form a positive regulatory network that promotes hair growth. Specifically, IGF1 stimulates the secretion of VEGFA, and activation of FGFR2 enhances the expression of IGF1, thus constituting a self-amplifying hair follicle maintenance system.

[0023] To test the effects of different components of hair follicle activating powder (5) on the expression of related genes in human follicle dermal papilla cells (HFDPC), the following experimental tests were conducted. As shown in Table 1 below, the experimental design included: a control group containing only human follicle dermal papilla cells (HFDPC); experimental group 1, in which sample 1 with a concentration of 200 µg / mL was added to human follicle dermal papilla cells (HFDPC), and sample 1 contained: hydrolyzed egg yolk powder, pea extract, and bird's nest extract; experimental group 2, in which sample 2 with a concentration of 200 µg / mL was added to human follicle dermal papilla cells (HFDPC), and sample 2 contained: compound vitamin C, comprehensive vitamin B complex, compound ferrous glycine, and zinc glycate; and experimental group 3, in which sample 2 with a concentration of 200 µg / mL was added to human follicle dermal papilla cells (HFDPC). Sample 3, at µg / mL, contains: hydrolyzed egg yolk powder, pea extract, bird's nest extract, compound vitamin C, B complex vitamins, ferrous glycinate, and zinc glycine. Understandably, samples 1 through 3 have undergone MTT assays to confirm that each sample is not toxic to human follicular dermal papillary cells (HFDPCs) and does not cause cell death. Table 1. Additives for each experimental group Test cells Added ingredients control group Human follicular dermal papillary cells (HFDPC) none Experimental group 1 Hydrolyzed egg yolk powder, pea extract, and bird's nest extract Experimental group 2 Compound vitamin C, comprehensive B vitamins, ferrous glycinate, and zinc glycine Experimental group 3 Hydrolyzed egg yolk powder, pea extract, bird's nest extract, compound vitamin C, B complex vitamins, ferrous glycinate, and zinc glycine.

[0024] More preferably, as shown in Table 2 below, the gene expression results of vascular endothelial growth factor A (VEGFA) in each group after different reaction times are as follows: VEGFA is a key growth factor for hair follicle microvascular formation and oxygen and nutrient supply. Increased expression of VEGFA can improve the microcirculation environment of hair follicles, thereby promoting the metabolism of human dermal papillary cells (HFDPC) and the nutrient acquisition of hair matrix cells. Minoxidil promotes hair growth through the above mechanism. From the results of each embodiment, it can be seen that samples 1 to 3 can significantly increase the gene expression of vascular endothelial growth factor A (VEGFA). Therefore, it can be inferred that samples 1 to 3, like minoxidil, have the potential to promote blood flow and hair follicle activation. In addition, in Example 1, after adding Sample 1 and reacting for 24 hours, it was found that the gene expression level of vascular endothelial growth factor A (VEGFA) still showed a significant increase, indicating that Sample 1 can activate human follicular dermal papillary cells (HFDPC) for a long time to promote hair follicle nutrition supply and angiogenesis, and has the potential to serve as a functional material to promote hair follicle activity and strengthen hair roots. Table 2. Gene expression results of vascular endothelial growth factor A (VEGFA) in each group reaction time 6 hours later 24 hours Relative gene expression level of VEGFA (Multiple of the control group's performance) control group 1 1 Experimental group 1 6.5 20.8 Experimental group 2 3.4 11.3 Experimental group 3 4.9 15.8

[0025] Even better, as shown in Table 3 below, the gene expression results of fibroblast growth factor receptor 2 (FGFR2) in each group after different reaction times are as follows: each sample has the potential to activate human follicular dermal papilla cells (HFDPC) growth signals and enhance regeneration capacity. It is speculated that protein hydrolysates or peptide factors may promote the efficiency of cell signal transduction, thereby enhancing the metabolism and renewal of hair follicle cells. Specifically, samples 1 to 3 can maintain the activity and regenerative capacity of human follicular dermal papilla cells (HFDPC), thereby maintaining hair follicle health and promoting hair growth. Table 3. Gene expression results of fibroblast growth factor receptor 2 (FGFR2) in each group reaction time 6 hours later 24 hours Relative gene expression level of FGFR2 (Multiple of the control group's performance) control group 1 1 Experimental group 1 1.8 1.4 Experimental group 2 1.1 1.8 Experimental group 3 1.8 1.6

[0026] Even better, as shown in Table 4 below, the gene expression results of insulin-like growth factor 1 (IGF1) in each group after different reaction times are as follows: by activating the growth factor pathway, it can promote the proliferation of hair matrix cells and delay the hair follicle degeneration process, thereby achieving the effects of strengthening hair roots, promoting hair follicle regeneration, and prolonging the hair follicle growth phase, and can be used as a raw material for the development of hair growth and scalp care products. Table 4. Gene expression results of insulin-like growth factor 1 (IGF1) in each group reaction time 6 hours later 24 hours Relative gene expression level of IGF1 (Multiple of the control group's performance) control group 1 1 Experimental group 1 7.6 7.4 Experimental group 2 3.8 3.7 Experimental group 3 5.8 5.7

[0027] Based on the above experimental results, the advantages of this invention compared to the previous technology are as follows: This invention encapsulates the hair follicle activation powder (5) in the accommodating space (4) defined by the first shell (2) and the second shell (3). Since the hair follicle activation powder (5) contains proteins, plant extracts, vitamins, and minerals, but does not contain potent drug ingredients, it has low irritation and almost no side effects. It will not cause cardiovascular stress or affect endocrine function, and can be applied to a wider range of people. In addition, after oral administration and absorption by the human body, the hair follicle activating powder (5) can increase the gene expression of vascular endothelial growth factor A (VEGFA), fibroblast growth factor receptor 2 (FGFR2), and insulin-like growth factor 1 (IGF1) in human hair follicle dermal papillary cells (HFDPC). Therefore, it can promote hair follicle nutrition and angiogenesis, maintain hair follicle health, promote hair follicle regeneration, prolong the hair follicle growth phase, promote hair growth, and strengthen hair roots. It has the potential to be used as a hair care product, health care product, or nutritional product.

[0028] The above description is merely a preferred embodiment of this invention and should not be construed as limiting the scope of its implementation. Any simple equivalent changes and modifications made based on the claims and description of this invention are still within the scope of this invention. Furthermore, no embodiment or claim needs to achieve all the objectives, advantages, or features disclosed in this invention. Additionally, the abstract and headings are merely for assisting in patent document searches and are not intended to limit the scope of this invention. Moreover, the terms "first," "second," etc., used in the specification are only used to indicate the names of components and are not intended to limit the upper or lower limits of the number of components.

[0029] 1: Oral capsules 2: First shell 3: Second shell 4: Storage space 5: Hair follicle activating powder 6: First hollow tube body 7: First closed end 8: First Open Terminal 9: First containment subspace 10: Second hollow tube body 11: Second closed end 12: Second Open Terminal 13: Second containment subspace

Claims

1. An oral capsule comprising: a first shell; a second shell, wherein one end of the first shell is detachably connected to one end of the second shell, such that the interior of the first shell and the interior of the second shell define an accommodating space; and a hair follicle activating powder contained in the accommodating space.

2. The oral capsule as described in claim 1, wherein: This hair follicle activating powder contains: hydrolyzed egg yolk powder, pea extract, and bird's nest extract.

3. The oral capsule as described in claim 1, wherein: This hair follicle activating powder contains: compound vitamin C, comprehensive B vitamins, compound ferrous glycine, and zinc glycate.

4. The oral capsule as described in claim 1, wherein: This hair follicle activating powder contains: hydrolyzed egg yolk powder, pea extract, bird's nest extract, compound vitamin C, B complex vitamins, compound ferrous glycine, and zinc glycate.

5. The oral capsule as described in claim 1, wherein: When applied to human follicle dermal papilla cells (HFDPC), this hair follicle activating powder can promote the gene expression of vascular endothelial growth factor A (VEGFA), fibroblast growth factor receptor 2 (FGFR2), and insulin-like growth factor 1 (IGF1) in human follicle dermal papilla cells (HFDPC).

6. The oral capsule as described in claim 1, wherein: The components of the first shell and the second shell include: pure water, colorant, thickener, anti-brittleness agent, gelatin, hydroxypropyl methylcellulose (HPMC), gellan gum, or pullulan.

7. The oral capsule as described in claim 1, wherein: The first housing or the second housing is transparent, translucent, or opaque.

8. The oral capsule as described in claim 1, wherein: The first housing includes: a first hollow tube; a first closed end formed at one end of the first hollow tube; a first open end formed at the other end of the first hollow tube; and a first accommodating subspace formed inside the first housing and communicating with the first open end; and the second housing includes: a second hollow tube; a second closed end formed at one end of the second hollow tube; and a second open end formed at the other end of the second hollow tube. And a second accommodating subspace is formed inside the second housing and connected to the second open end, wherein: the first open end of the first housing extends from the second open end of the second housing into the second accommodating subspace and engages with the inner edge of the second housing to define the accommodating space.

9. The oral capsule as described in claim 8, wherein: The first hollow tube and the second hollow tube are both circular tubes, and the outer diameter of the first hollow tube is less than or equal to the inner diameter of the second hollow tube.

10. The oral capsule as described in claim 8, wherein: The first closed end and the second closed end are shaped like hemispherical shells.

Images